ClinicalTrials.gg
CompletedNCT04243863Updated Dec 3, 2025

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

A Phase 1 interventional study of VNRX-7145 and Placebo in Healthy Volunteers, sponsored by Basilea Pharmaceutica. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • VNRX-7145
  • Safety
  • Pharmacokinetics
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults 18-45 years
  • Males or non-pregnant, non-lactating females
  • (BMI): ≥18.5 kg/m² and ≤32.0 kg/m²
  • Normal blood pressure
  • Normal laboratory tests

Exclusion criteria

Exclusion Criteria:

  • Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, , hematologic, neoplastic, or neurological disorder
  • History of drug allergy
  • Abnormal or history of abnormal rhythm disorder
  • Positive alcohol, drug, or tobacco use/test
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    VNRX-7145

    Oral dosing

    Drug: VNRX-7145

  • Placebo comparator
    Placebo

    Oral dosing

    Drug: Placebo

Interventions

  • Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)

  • DrugPlacebo

    Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)

06

What researchers measure

Primary outcomes

  1. Part 1: Number of subjects with adverse events

    Time frame: Day 8

  2. Part 2: Number of subjects with adverse events

    Time frame: Day 17

Secondary outcomes

  1. Part 1: AUC0-tau

    Time frame: Days 1-3

  2. Part 1: Cmax

    Time frame: Days 1-3

  3. Part 1: tmax

    Time frame: Days 1-3

  4. Part 1: CLr

    Time frame: Days 1-3

  5. Part 2: AUC0-tau

    Time frame: Days 1-10

  6. Part 2: Cmax

    Time frame: Days 1-10

  7. Part 2: tmax

    Time frame: Days 1-10

  8. Part 2: CLr

    Time frame: Days 1-10

07

Study locations

1 site
  • Worldwide Clinical Trials Early Phase Services, LLC
    San Antonio, Texas 78217, United States
08

References and documents

Publications

  • de Oliveira CF, Dorr MB, van de Wetering J, Lowe K, Sabato P, Winchell G, Chen H, McGovern PC. Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers. Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0021025. doi: 10.1128/aac.00210-25. Epub 2025 Aug 5. PubMed 40762486 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2021, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 28, 2020
StartActual
Jan 20, 2020
Primary completionActual
Apr 5, 2021
CompletionActual
Apr 5, 2021
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04243863
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Jan 20, 2020
Primary completion
Apr 5, 2021
Completion
Apr 5, 2021
Last update
Dec 3, 2025

Study contacts

Kamal Hamed, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledaborbactam etzadroxil

Start the discussion